Literature DB >> 33377996

Improving the trustworthiness of findings from nutrition evidence syntheses: assessing risk of bias and rating the certainty of evidence.

Lukas Schwingshackl1, Holger J Schünemann2, Joerg J Meerpohl3,4.   

Abstract

Suboptimal diet is recognized as a leading modifiable risk factor for non-communicable diseases. Non-randomized studies (NRSs) with patient relevant outcomes provide many insights into diet-disease relationships. Dietary guidelines are based predominantly on findings from systematic reviews of NRSs-mostly prospective observational studies, despite that these have been repeatedly criticized for yielding potentially less trustworthy results than randomized controlled trials (RCTs). It is assumed that these are a result of bias due to prevalent-user designs, inappropriate comparators, residual confounding, and measurement error. In this article, we aim to highlight the importance of applying risk of bias (RoB) assessments in nutritional studies to improve the credibility of evidence of systematic reviews. First, we discuss the importance and challenges of dietary RCTs and NRSs, and provide reasons for potentially less trustworthy results of dietary studies. We describe currently used tools for RoB assessment (Cochrane RoB, and ROBINS-I), describe the importance of rigorous RoB assessment in dietary studies and provide examples that further the understanding of the key issues to overcome in nutrition research. We then illustrate, by comparing the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach with current approaches used by United States Department of Agriculture Dietary Guidelines for Americans, and the World Cancer Research Fund, how to establish trust in dietary recommendations. Our overview shows that the GRADE approach provides more transparency about the single domains for grading the certainty of the evidence and the strength of recommendations. Despite not increasing the certainty of evidence itself, we expect that the rigorous application of the Cochrane RoB and the ROBINS-I tools within systematic reviews of both RCTs and NRSs and their integration within the GRADE approach will strengthen the credibility of dietary recommendations.
© 2020. The Author(s).

Entities:  

Keywords:  Dietary guidelines; GRADE; Meta-analysis; Nutrition evidence; Risk of bias; Systematic reviews; Trustworthiness

Mesh:

Year:  2020        PMID: 33377996      PMCID: PMC8354882          DOI: 10.1007/s00394-020-02464-1

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


Introduction

Non-communicable diseases (NCDs) account for over 70% of total deaths worldwide [1]. According to the Global Burden of Disease studies, suboptimal diet is the leading risk factor for ~ 50% of disabilities from cardiovascular diseases [2]. As in many other areas, systematic reviews (SRs) have been established as the method of choice to synthesize data from primary research studies in the field of nutrition. Hence, the Global Burden of Disease studies, as well as dietary guidelines are based on findings from SRs. Many of these SRs do not exclusively include randomized controlled trials (RCTs), but rely primarily on non-randomized studies (NRSs: in this article the term “NRS” is used exclusively as a synonym for cohort studies), for example prospective cohort studies, because RCTs are not available or considered not applicable [3, 4]. The acceptance of SRs as the main basis for dietary guidelines, Global Burden of Disease studies, and public health nutrition policies constitutes a great opportunity for strengthening the repeatedly criticized trustworthiness (in this article the term “trustworthiness” is used exclusively as a synonym for certainty of evidence [5]) of dietary recommendations [6]. We begin by highlighting the importance and challenges of dietary RCTs and NRSs, and provide potentially less trustworthy results of NRSs, by reporting examples of discordance between findings of RCTs and NRSs. We describe the importance of rigorous risk of bias (RoB) assessment in such studies and provide examples that help understanding the key issues to overcome. We then illustrate, by comparing the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach with current approaches (used by United States Department of Agriculture Dietary Guidelines for Americans [7], and the World Cancer Research Fund [8]), how to establish trust in dietary recommendations.

Why we need more RCTs, and why RCTs are difficult to conduct in the nutrition field?

We need good science to trust dietary advice, ideally unbiased and direct evidence from RCTs to overcome bias. RCTs, if well-designed and -conducted, give robust answers to the research questions they address and are widely encouraged as the ideal methodology for causal inference [9]. However, due to the difficulty of inducing and maintaining dietary changes, randomization to allocate people to alternative diets and to investigate effects of long-term lifestyle behaviors on patient relevant outcomes remains challenging (Table 1). RCT methodologies are accompanied by a number of specific challenges in nutritional research. First, in dietary RCTs, it is often impossible to ensure that participants are unaware of their treatment (except for placebo RCTs of dietary supplements) because people are generally aware of what they are eating. Second, in nutrition research trials, low adherence to a specific dietary regimen is often observed. Third, investigating effects of long-term lifestyle behaviors on patient relevant outcomes is difficult. Well-controlled feeding trials could overcome some of these limitations, since study participants are expected to adhere to strict diet by consuming only food provided by the research kitchen [10]. Moreover, supermarket models have been implemented successfully in RCTs in which the participants receive all groceries free of charge for a period of time, for example, for 6–12 months, in a university supermarket. Bar codes and special computer programs were used to monitor and examine whether the participants followed the right composition of the diets they were allocated to. These intervention models work best for single people, and therefore, generalizability of the results is limited for the general population. Biomarkers of intake have shown that this is a superior method to ensure high compliance and, hence, good validity of the efficacy of the diet intervention [11, 12].
Table 1

Strengths and limitations of randomized controlled trials (RCTs) and non-randomized studies (NRSs)

RCTsNRSs
Theoretical
 Certainty of the evidence regarding causalityHigherLower
 ConfoundingUnlikely for large RCTsAdjustment for known and measured confounders possible; residual confounding likely
 Levels of exposureFew; often relatively high differences in intervention groupsBroad range, possibility of stratifying by exposure level
 Follow-up time of studyShort or limitedLong
Empirical
 Number of participantsUsually < 1000Some > 10,000
 Representativeness for general populationOften limitedGenerally good
 Outcome measuresOften risk factor, occasionally morbidity/ mortalityUsually morbidity/ mortality
Strengths and limitations of randomized controlled trials (RCTs) and non-randomized studies (NRSs)

Why NRSs provide sometimes potentially less trustworthy results, and how we can identify plausible results?

NRSs, predominately prospective observational studies with patient relevant outcomes (e.g., cardiovascular disease), provide many insights into diet–disease relationships and are the most important source to derive updated Global Burden of Disease studies-reports and dietary guidelines for the primary prevention of NCDs until to date [13]. However, nutrition epidemiology has been repeatedly criticized for providing potentially less trustworthy results. For example, most nutrients not only have been associated with cancer risk but for several of the nutrients there are published reports that show an increased risk in one NRS and a decreased risk in another [14]. In the past, several RCTs comparing dietary interventions with placebo or control interventions have failed to replicate the (presumably protective) associations between dietary factors (e.g., nutrients) and risk for NCDs found in large scale cohort studies [15-19]. For example, RCTs found no evidence for a beneficial effect of fiber intake on CRC risk [20], vitamin E and cardiovascular disease (CVD) [21]. On the contrary, some consistent findings between cohort studies and RCTs have been reported as well (e.g., total fat and coronary heart disease or breast cancer) [22]. Recently, Ioannidis suggested that RCTs should largely replace NRSs in human nutrition research [14] due to the core limitations of NRSs, such as bias due to prevalent-user designs, inappropriate comparators, residual confounding, measurement error, and the fact that small effect sizes are common in nutrition research [23, 24]. Across dietary NRSs, social desirability biases are prevalent: Participants may give perceived “healthy” responses, such as over-reporting fruit and vegetable intake or underestimating fat intake [25], whereas obese patients are more likely to underreport nutritional intake, particularly energy, which can lead to the underestimation of the intake of dietary components assessed [26]. Unfortunately, common tools used to measure dietary adherence in not only NRSs but also RCTs, such as food frequency questionnaires, dietary records, or 24-h dietary recalls, are prone to measurement error [27]. Overall, nutritional research in general poses a number of specific challenges for various empirical approaches. We postulate that rigorous RoB assessment and the use of the GRADE approach to assess the certainty of the evidence could help to identify plausible results and to address some of the criticism levied at RCTs, NRSs, meta-analyses of such studies, and dietary guidelines, with the aim of overcoming disagreement between classic epidemiologists and interventionalists. This can be done by exploring the nature of potentially less trustworthy results, a process that is often omitted, inconsistently applied across studies, or flawed [28].

What tools should be used to address risk of bias?

At SR level, the established approach to evaluate the credibility of results from primary studies is RoB assessment. The RoB of a single RCT or RCTs included in a SR should be assessed with a well-established and validated tool, such as the RoB tool by Cochrane [29]. Within the Cochrane RoB tool for RCTs, RoB is assessed for six domains: (i) selection bias, (ii) performance bias, (iii) attrition bias, (iv) detection bias, (v) reporting bias, and (vi) other bias (e.g., carry-over effects in cross-over trials) (Table 2) [29]. In a previous analysis of 50 (18% of them Cochrane Reviews) randomly selected nutrition-specific SRs of RCTs [23], it was shown that 70% used the Cochrane RoB assessment tool [23, 29], 14% reported no RoB assessment, 10% the Jadad Scale [30], and 6% applied their own score. Recently, the RoB 2.0 tool has been published [31]. To this day, dietary adherence has not been included as a specific RoB domain in the Cochrane RoB tool. However in the Cochrane RoB tool 2.0, lack of adherence to a specific dietary intervention will be evaluated within the bias domain assessing deviations from intended interventions [31].
Table 2

Comparison of risk of bias domains in RCTs and NRSs, and example of the application of the ROBINS-I tool in a recent meta-analysis investigating the association between adherence to a Mediterranean diet and risk of stroke [51], and the corresponding quality rating by applying the Newcastle–Ottawa Scale

Bias in RCTsAction that protect against biasesBias in NRSsROBINS-INewcastle–Ottawa Scale (max. 9 points)
(Cochrane RoB tool)DomainsRating (n = studies, %)DomainsRating (n = studies, %)
Bias arising from randomization processRandom sequence generationConfoundingBias due to ConfoundingModerate RoB20/20 (100%)Comparability of cohorts on the basis of the design or analysisHigh quality20/20 (100%)
Allocation concealmentLow quality0/20 (0%)
SelectionBias in selection of participants into the studyLow RoB16/20 (80%)Representativeness of the exposed cohortHigh quality13/20 (65%)
Low quality7/20 (35%)
Serious RoB4/20 (20%)Selection of the non-exposed cohortHigh quality20/20 (100%)
Low quality0/20 (0%)
Demonstration that outcome of interest was not present at start of studyHigh quality20/20 (100%)
Low quality0/20 (0%)
MisclassificationBias in classification of exposureLow RoB16/20 (80%)Ascertainment of exposureHigh quality18/20 (90%)
Low quality2/20 (10%)
Moderate RoB2/20 (10%)
Serious RoB2/20 (10%)
Bias due to deviations from intended interventionBlinding of participants and personnelPerformanceBias due to deviations from intended exposureLow RoB1/20 (5%)N/A
Moderate RoB19/20 (95%)
Bias due to missing outcome dataComplete outcome dataAttritionBias due to missing outcome dataLow RoB15/20 (75%)Adequacy of follow-up of cohortsHigh quality19/20 (95%)
Moderate RoB5/20 (25%)Low quality1/20 (5%)
Bias in measurement of the outcomeBlinding of outcome assessmentDetectionBias in measurement of the outcomeLow RoB19/20 (95%)Assessment of outcomeHigh quality20/20 (100%)
Serious RoB1/20 (5%)
Low quality0/20 (0%)
Was follow-up long enough for outcomes to occur?High quality20/20 (100%)
Low quality0/20 (0%)
Bias in the selection of the reported resultsAvoid selective reportingReportingBias in the selection of the reported resultsLow RoB14/20 (70%)N/A
Moderate RoB3/20 (15%)
Serious RoB3/20 (15%)
Overall RoB judgementaLow RoB0/20 (0%)Overall study qualitybHigh quality (7–9)20/20 (100%)
Moderate RoB13/20 (65%)Lower quality (0–6)0/20 (0%)
Serious RoB7/20 (35%)

N/A not applicable, RoB risk of bias, ROBINS-I risk of bias in non-randomized studies of interventions

For ROBINS-I overall RoB judgements across studies were based to the most severe of the RoB item-level judgments. Since no single study was judged as low RoB for the domain “confounding”, also in the overall judgement no study was judged with a low RoB

For the Newcastle–Ottawa Scale, overall study quality judgements across studies were based on points (0–9). If a single study reached ≥ 7 points, it was defined as high-quality study

Comparison of risk of bias domains in RCTs and NRSs, and example of the application of the ROBINS-I tool in a recent meta-analysis investigating the association between adherence to a Mediterranean diet and risk of stroke [51], and the corresponding quality rating by applying the Newcastle–Ottawa Scale N/A not applicable, RoB risk of bias, ROBINS-I risk of bias in non-randomized studies of interventions For ROBINS-I overall RoB judgements across studies were based to the most severe of the RoB item-level judgments. Since no single study was judged as low RoB for the domain “confounding”, also in the overall judgement no study was judged with a low RoB For the Newcastle–Ottawa Scale, overall study quality judgements across studies were based on points (0–9). If a single study reached ≥ 7 points, it was defined as high-quality study Focusing on NRSs, a SR identified 86 tools to assess study quality in NRSs showing high inconsistency in selection/inclusion and weighting of domains across tools [32]. In 50 nutrition-specific SRs of NRSs, it was shown that in 40% of these, no study quality assessment was done [23], 38% used the Newcastle–Ottawa Scale, while the remaining 22% used a variety of other, less well-established tools. When using Newcastle–Ottawa Scale, the most widely applied tool, each study will be judged in relation to eight items (Table 2). However, Stang [33] criticized the NOS for its arbitrary definitions and concluded that this score appeared to be unacceptable for the assessment of study quality, of NRSs. An empirical study has recently shown a fundamental problem when applying the NOS: out of 89 observational nutritional studies, 81 studies (91%) included in 14 meta-analyses were rated as high-quality studies [34]. The threshold to define high quality is apparently so low within NOS that there is no discriminatory effect when applying NOS. The term “study quality” is often used in this context interchangeably with RoB, but it is important to distinguish between quality and RoB. The term suggests an investigation of the extent to which study authors conducted their research to the highest possible standards. A study may be performed to the highest possible standards yet still have an important RoB. For example, often it is impractical or impossible to blind participants or study personnel to the intervention group. It is inappropriately judgmental to describe all such studies as of “low quality”, but that does not mean they are free of bias resulting from knowledge of intervention status [35]. Moreover, reporting a study (quality) in line with reporting guidelines such as the CONSORT statement (for RCTs) [36] or the STROBE statement [37] is unlikely to have direct implications for risk of bias. To overcome the problems of the NOS, the risk of bias in non-randomized studies of interventions (ROBINS-I) tool has been developed, and published in 2016 [38] (Table 2). A modified version to assess the RoB in non-randomized studies of exposures (ROBINS-E) is under development, and adaptation of ROBINS for exposure studies is ongoing [39]. For example, Morgan and colleagues published recently a user’s guide on how to apply, interpret, and present the results of ROBINS to assess the RoB in NRSs dealing with effects of exposures (e.g., bisphenol A) on health outcomes (e.g., obesity) [40]. In their user’s guide, the authors applied the draft ROBINS-(exposure) tool successfully, to a variety of study designs including prospective cohort studies and cross-sectional studies [40]; ROBINS-E was also recently used to evaluate RoB in case–control studies [41]. Detailed methods of the application of ROBINS-I and the current development of a RoB instrument for NRSs of exposures have been described in detail by Morgan and colleagues [42]. For example, domains 3 (“bias in classification of interventions”) and 4 (“bias due to departures from intended interventions”) of ROBINS-I have been changed to “bias in classification of exposures” and “bias due to departures from exposures” [42] (Table 2). The COSMOS-E reporting guideline (Conducting Systematic Reviews and Meta-Analyses of Observational Studies of Etiology) has recently been published; COSMOS-E also recommends the use of the ROBINS tool to evaluate RoB in observational studies, and the GRADE approach to rate the certainty of evidence [43]. GRADE is not recommending a specific tool to assess RoB, however, because the tools have different advantages and disadvantages that influence the choice. As long as RoB is assessed across studies, any validated and appropriate tool can be used.

Examples of critical risk of bias in certain domains in a dietary Cochrane Review

To exemplify the usage and judgements of Cochrane RoB domains for dietary RCTs, we chose a highly cited Cochrane Review on Mediterranean diet (MedDiet) and prevention of CVD, which included 49 papers. In this Cochrane Review, the authors took into account the difficulties of blinding participants (although, double blinded designs are not always ideal for providing a reliable answer to the trial’s research question [44]) in dietary interventions and rated this as unclear rather than high RoB [45]. The procedure of the author’s shows that especially for the RoB assessment of dietary RCTs, a puristic approach to judge RoB is not always sensible. Dietary adherence is probably the most important limitation of dietary RCTs, mainly in long-term RCTs [46]. Not only has dietary adherence not been assessed as a RoB item to date, but also many SRs do not even investigate dietary adherence at all, like our exemplary chosen Cochrane Review on MedDiet and CVD [45]. Difficulty of attrition (in free living populations, a 40–50% dropout rate is fairly common [47]) is mainly observed in longer-term dietary RCTs [48]. In the Cochrane Review on the MedDiet and CVD, only two out of 30 RCTs conducted intention-to-treat analyses, and only 11 RCTs were rated with a low RoB for attrition bias [45].

Why is risk of bias so important to evaluate the credibility of study results?

Sensitivity analyses including only low RoB- or excluding high-RoB RCTs are an important means to explore the impact of bias on pooled results in a meta-analysis. A methodology study evaluating 59 SRs showed that only 50% of these SRs conducted sensitivity analyses for low RoB studies [49]. In some circumstances, when conducting sensitivity analyses excluding trials with a high RoB, significant summary estimates become statistically non-significant or vice versa. For example, in a large Cochrane Review investigating the effects of antioxidant supplements for prevention of mortality, risk increasing effects for beta-carotene and vitamin E were only observed in the sensitivity analyses for low RoB RCTs, whereas the primary analysis showed no effects [50]. Because the ROBINS-I tool has only recently been published, it lacks application in nutrition-specific meta-analyses. A recent SR of NRSs investigating the relationship between adherence to the Mediterranean Diet and risk of stroke applied the ROBINS-I tool [51]. Out of 20 included studies, no NRS was rated with a low RoB, 13 NRSs (65%) were rated as moderate RoB, and seven NRSs (35%) as serious RoB (Table 2). On the contrary, the application of the NOS in those studies resulted in a high-quality (low RoB) judgement for all 20 NRSs (Table 2). Rigorous application of the Cochrane RoB tool for RCTs and the ROBINS-I tool for NRSs, would improve evaluation of validity, transparency, interpretation and conclusions of a single dietary RCT or RCTs included in a SR.

Why can rating the certainty of evidence improve the trustworthiness of findings?

RoB assessment is a fundamental part of the GRADE approach. The GRADE working group [52] has developed a common and transparent approach for grading the certainty of evidence and strength of recommendations based on a body of evidence (e.g., SR of RCTs). GRADE is also used in the field of nutrition research [53]. The GRADE approach classifies bodies of RCTs as initially starting at high certainty and bodies of NRSs at initially starting at low certainty [54]. In 2016, the NutriGrade scoring system by Schwingshackl and colleagues was published [23]. The main proposed adaptation of GRADE was a modified initial classification of a body of evidence of RCTs and cohort studies. NutriGrade, and its proposed adaptations was discussed extensively in the scientific community [55, 56]. Afterwards, the GRADE working group has acknowledged limitations that in certain research fields (e.g., nutrition research), RCTs on patient relevant outcomes (e.g., cardiovascular disease) are sparse or not feasible, and that the application of the current GRADE approach to classify study designs might be limited. It has been pointed out that using the GRADE approach, in particular in relation to RoB assessment, is challenging and may lead to excessive downgrading. For example, GRADE users may inappropriately double count the risk of confounding and selection bias by downgrading the initial body of evidence to low, followed by further downgrading due to unknown confounders [23, 56–58]. Therefore, guidance on how to assess the certainty of evidence within GRADE when ROBINS-I is being used was published in 2018. RoB instruments, such as ROBINS that allow for the comparison of a body of evidence from NRSs to RCTs eliminate the GRADE requirement for starting an assessment of a body of evidence as “high” or “low” certainty based on study design (Table 3) [57]. This will lead to a better comparison of evidence from RCTs and NRSs because they are placed on a common metric for RoB. Due to its enhanced development we are now suggesting the GRADE approach to rate the certainty of the evidence.
Table 3

Main methodological differences between the GRADE approach [54], and approaches taken by the 3rd World Cancer Research Fund/ American Institute for Cancer Research Expert report [8], and the USDA Dietary Guidelines for Americans 2015–2020 [7] to rate the certainty of evidence

Macro-levelMicro-levelGRADE3rd WCRF/AICR ReportaUSDA DGA 2015–2020b
Y/N/UExplanationY/N/UExplanationY/N/UExplanation
A priori assumptionBody of evidence (RCTs and cohort studies) begins as high certaintyNUsing NOSYN/AYN/A
YUsing ROBINS-I
Certainty criteriaRisk of bias (aka study quality)Y

Cochrane RoB tool for RCTs;

NOS or ROBINS-I for NRS

UNo tool; some criteria reported: confounding, measurement error and selection bias (but assessment unclear)YTool adapted from Cochrane: selection bias, performance bias, detection bias, attrition bias
InconsistencyYSimilarity of point estimates, extent of overlap of 95% CI, statistical criteria including tests of heterogeneity, and I2YI2UDescription vague: e.g., consistent in direction and size of effect or degree of association and statistical significance with very minor exceptions
IndirectnessYAccording to PICO criteriaNN/AYAccording to PICO criteria
ImprecisionYExamination of 95% CI, OISNN/AULarge sample size
Publication biasYFunnel plotNN/ANN/A
Large effectY

RR: > 2 or < 0.5 (large effect)

RR: > 5 or < 0.2 (very large effect)

YRR: > 2 (large effect)UDescription vague: e.g., clinically meaningful effect size
Dose–responseYLinear, non-linearYLinear, non-linearNN/A
Plausible residual confoundingYPlausible confounders would decrease an effect, or would create a spurious effect when results suggest no effectNN/ANN/A
Transparent SummarySummary of Findings TableYCertainty rating (and criteria) for each outcome and the estimate of effectNN/ANN/A
Overall ratingCertainty of evidenceHigh, Moderate, Low, Very lowConvincing, Probable, Limited-suggestive, Limited-no conclusion, Substantial effect on risk unlikelyStrong, Moderate, Limited, Grade not assignable

95% CI 95% confidence interval, I inconsistency, N no, N/A not applicable, NOS Newcastle Ottawa Scale, OIS optimal information size, PICO population, intervention, comparison, outcome, ROBINS-I risk of bias in non-randomized studies of interventions, RR risk ratio, U unclear; Y: yes

aWorld Cancer Research Fund/American Institute for Cancer Research report is the most comprehensive global research project on diet, and physical activity and cancer risk or survival [8]

bThe United States Department of Agriculture’s Dietary Guidelines for Americans 2015–2020 are the most comprehensive guidance for healthy eating in the US and worldwide [7]

Main methodological differences between the GRADE approach [54], and approaches taken by the 3rd World Cancer Research Fund/ American Institute for Cancer Research Expert report [8], and the USDA Dietary Guidelines for Americans 2015–2020 [7] to rate the certainty of evidence Cochrane RoB tool for RCTs; NOS or ROBINS-I for NRS RR: > 2 or < 0.5 (large effect) RR: > 5 or < 0.2 (very large effect) 95% CI 95% confidence interval, I inconsistency, N no, N/A not applicable, NOS Newcastle Ottawa Scale, OIS optimal information size, PICO population, intervention, comparison, outcome, ROBINS-I risk of bias in non-randomized studies of interventions, RR risk ratio, U unclear; Y: yes aWorld Cancer Research Fund/American Institute for Cancer Research report is the most comprehensive global research project on diet, and physical activity and cancer risk or survival [8] bThe United States Department of Agriculture’s Dietary Guidelines for Americans 2015–2020 are the most comprehensive guidance for healthy eating in the US and worldwide [7] The GRADE domains: RoB, inconsistency, indirectness, imprecision, publication bias, large effect, dose–response, and direction of plausible residual confounding are taken into account to arrive at the certainty of the evidence for a given outcome across studies (Table 3). Overall, GRADE specifies four levels of certainty of evidence: high, moderate, low, and very low. For example, high certainty of evidence is defined as: “High certainty that a true effect lies on one side of a specified threshold or within a chosen range” [5]. Guideline authors then consider the direction and strength of recommendation (strong vs. conditional) [59] based on overall certainty of evidence across outcomes and in light of various other criteria including values or importance of the outcomes, resource use, equity, acceptability and feasibility [60]. Although only few nutrition-specific SRs have evaluated the certainty of evidence so far, the GRADE approach is now being applied increasingly in nutrition research [23, 58].

What are current approaches for making dietary recommendations?

Table 3 highlights the main methodological differences in rating the certainty of evidence by comparing the GRADE approach with the approaches by the WCRF [8] and the USDA Dietary Guidelines for Americans 2015–2020 [7]. Overall, the GRADE approach provides more transparency about the single domains. Separating certainty of the evidence assessment from confidence in a recommendation and decision will bring clarity to the field, lead to better research and could overcome the incommunicado between different stakeholders. Table 4 highlights the Evidence to Decision (EtDs) framework which aims to use evidence in a systematic and transparent way to inform decisions established by the GRADE working group [61]. Guidelines approaches neither by the WCRF nor the USDA have integrated patient and community values and preferences, nor applied strict safeguards against conflicts of interest. However, several components of the EtDs framework have been addressed to be implemented in future UDSA dietary guidelines. In the future, developers of recommendations should take a population perspective for general public health nutrition recommendations, and may consider also biological plausibility or sustainability, which are highly relevant for dietary recommendations [62, 63]. Biological plausibility is a domain which is considered by the WCRF to rate the certainty of evidence [8], whereas GRADE does not consider the issue of biological plausibility as domain of certainty. GRADE argues that biological plausibility is considered in three ways: (1) during question formulation; (2) in the evaluation of other, indirect evidence (e.g., similar nutrient or population); and (3) how directly the intervention affects a surrogate outcome [64].
Table 4

Main methodological differences between the GRADE Evidence to Decisions framework [60], and approaches taken by the 3rd World Cancer Research Fund/ American Institute for Cancer Research Expert report [8], and the USDA Dietary Guidelines for Americans 2015–2020 [7]

Macro-levelMicro-levelGRADE3rd WCRF/AICR ReportaUSDA DGA 2015–2020b
Y/N/UExplanationY/N/UExplanationY/N/UExplanation
Conflict of interest from committee membersIntellectual and financial conflictsYShould be reportedNNot reportedUPer Federal Advisory Committee Act rules, Advisory Committee members were thoroughly vetted for conflicts of interest before they were appointed to their positions and were required to submit a financial disclosure form annually
EtDs frameworkProblemYProblem priority definition?UN/AUN/A
Benefit and harmsYHow substantial are beneficial/harmful effects?UN/ANN/A
Certainty of evidenceYsee Table 2Ysee Table 2Ysee Table 2
ValuesYHow much people value the main outcomes?NN/ANN/A
Balance of effectsYBalance between desirable and undesirable effects?NPanel has sometimes not made recommendations despite strong evidence; because of potentially adverse effects (dairy and prostate cancer) on one cancer despite evidence of protection for another (e.g., dairy and colorectal cancer)NN/A
Resources requiredYHow large are the costs?NN/ANN/A
Cost effectivenessYCost effectiveness of the intervention?NN/ANN/A
EquityYImpact on health equity?NN/ANN/A
AcceptabilityYOption acceptable to key stakeholders?NN/ANN/A
FeasibilityYImplementation feasible?USometimes not feasibleNN/A
RecommendationStrength of recommendationYStrong, weak (conditional, discretional, or qualified)YRecommendations were made only when the CUP Panels judged the evidence sufficiently strong (when exposure was convincingly/probably or causally linked to cancer risk)UThe grades used for conclusion statements also fall into one of four categories (as the certainty of evidence evaluation): strong, moderate, limited, and grade not assignable

CUP continuous update project, EtDs Evidence to Decisions, N no, N/A not applicable, U unclear, Y yes

aWorld Cancer Research Fund/American Institute for Cancer Research report is the most comprehensive global research project on diet, and physical activity and cancer risk or survival [8]

bThe United States Department of Agriculture’s Dietary Guidelines for Americans 2015–2020 are the most comprehensive guidance for healthy eating in the US and worldwide [7]

Main methodological differences between the GRADE Evidence to Decisions framework [60], and approaches taken by the 3rd World Cancer Research Fund/ American Institute for Cancer Research Expert report [8], and the USDA Dietary Guidelines for Americans 2015–2020 [7] CUP continuous update project, EtDs Evidence to Decisions, N no, N/A not applicable, U unclear, Y yes aWorld Cancer Research Fund/American Institute for Cancer Research report is the most comprehensive global research project on diet, and physical activity and cancer risk or survival [8] bThe United States Department of Agriculture’s Dietary Guidelines for Americans 2015–2020 are the most comprehensive guidance for healthy eating in the US and worldwide [7]

Conclusion

Despite not increasing the certainty of evidence itself, we expect that the rigorous application of the Cochrane RoB and the ROBINS-I tools within SRs of both RCTs and NRSs and their integration within the GRADE approach will strengthen the credibility of dietary recommendations.

Financial support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.
  51 in total

Review 1.  Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis.

Authors:  Linda L Humphrey; Rongwei Fu; Kevin Rogers; Michele Freeman; Mark Helfand
Journal:  Mayo Clin Proc       Date:  2008-11       Impact factor: 7.616

2.  The Challenge of Reforming Nutritional Epidemiologic Research.

Authors:  John P A Ioannidis
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272

Review 3.  Diet and Cardiovascular Disease: Advances and Challenges in Population-Based Studies.

Authors:  An Pan; Xu Lin; Elena Hemler; Frank B Hu
Journal:  Cell Metab       Date:  2018-03-06       Impact factor: 27.287

4.  Perspective: Challenges and Controversial Issues in the Dietary Guidelines for Americans, 1980-2015.

Authors:  Marion Nestle
Journal:  Adv Nutr       Date:  2018-03-01       Impact factor: 8.701

Review 5.  Generating the evidence for risk reduction: a contribution to the future of food-based dietary guidelines.

Authors:  Lukas Schwingshackl; Sabrina Schlesinger; Brecht Devleesschauwer; Georg Hoffmann; Angela Bechthold; Carolina Schwedhelm; Khalid Iqbal; Sven Knüppel; Heiner Boeing
Journal:  Proc Nutr Soc       Date:  2018-04-30       Impact factor: 6.297

6.  Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies.

Authors:  Anita Koushik; David J Hunter; Donna Spiegelman; Kristin E Anderson; Julie E Buring; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; Susanna C Larsson; Michael Leitzmann; James R Marshall; Marjorie L McCullough; Anthony B Miller; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Arthur Schatzkin; Leo J Schouten; Walter C Willett; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

7.  The GRADE Working Group clarifies the construct of certainty of evidence.

Authors:  Monica Hultcrantz; David Rind; Elie A Akl; Shaun Treweek; Reem A Mustafa; Alfonso Iorio; Brian S Alper; Joerg J Meerpohl; M Hassan Murad; Mohammed T Ansari; Srinivasa Vittal Katikireddi; Pernilla Östlund; Sofia Tranæus; Robin Christensen; Gerald Gartlehner; Jan Brozek; Ariel Izcovich; Holger Schünemann; Gordon Guyatt
Journal:  J Clin Epidemiol       Date:  2017-05-18       Impact factor: 6.437

8.  Health effect of the New Nordic Diet in adults with increased waist circumference: a 6-mo randomized controlled trial.

Authors:  Sanne K Poulsen; Anette Due; Andreas B Jordy; Bente Kiens; Ken D Stark; Steen Stender; Claus Holst; Arne Astrup; Thomas M Larsen
Journal:  Am J Clin Nutr       Date:  2013-11-20       Impact factor: 7.045

9.  Diets with high or low protein content and glycemic index for weight-loss maintenance.

Authors:  Thomas Meinert Larsen; Stine-Mathilde Dalskov; Marleen van Baak; Susan A Jebb; Angeliki Papadaki; Andreas F H Pfeiffer; J Alfredo Martinez; Teodora Handjieva-Darlenska; Marie Kunešová; Mats Pihlsgård; Steen Stender; Claus Holst; Wim H M Saris; Arne Astrup
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

10.  The 2015 Dutch food-based dietary guidelines.

Authors:  D Kromhout; C J K Spaaij; J de Goede; R M Weggemans
Journal:  Eur J Clin Nutr       Date:  2016-04-06       Impact factor: 4.016

View more
  12 in total

1.  Dietary glycemic index, glycemic load and cancer risk: a meta-analysis of prospective cohort studies.

Authors:  Tingting Long; Ke Liu; Jieyi Long; Jiaoyuan Li; Liming Cheng
Journal:  Eur J Nutr       Date:  2022-01-16       Impact factor: 5.614

Review 2.  Vegetarian and vegan diets and the risk of cardiovascular disease, ischemic heart disease and stroke: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Jarle Sæby Dybvik; Mette Svendsen; Dagfinn Aune
Journal:  Eur J Nutr       Date:  2022-08-27       Impact factor: 4.865

3.  An Empirical Evaluation of the Impact Scenario of Pooling Bodies of Evidence from Randomized Controlled Trials and Cohort Studies in Nutrition Research.

Authors:  Lukas Schwingshackl; Nils Bröckelmann; Jessica Beyerbach; Sarah S Werner; Jasmin Zähringer; Guido Schwarzer; Joerg J Meerpohl
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

4.  Evaluating Concordance of Bodies of Evidence from Randomized Controlled Trials, Dietary Intake, and Biomarkers of Intake in Cohort Studies: A Meta-Epidemiological Study.

Authors:  Jessica Beyerbach; Julia Stadelmaier; Georg Hoffmann; Sara Balduzzi; Nils Bröckelmann; Lukas Schwingshackl
Journal:  Adv Nutr       Date:  2022-02-01       Impact factor: 11.567

Review 5.  Chinese Medicine as an Adjunctive Treatment for Gastric Cancer: Methodological Investigation of meta-Analyses and Evidence Map.

Authors:  Cuncun Lu; Lixin Ke; Jieyun Li; Shuilin Wu; Lufang Feng; Youyou Wang; Alexios Fotios A Mentis; Peng Xu; Xiaoxiao Zhao; Kehu Yang
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

6.  A systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers.

Authors:  Lucy R Ellis; Sadia Zulfiqar; Mel Holmes; Lisa Marshall; Louise Dye; Christine Boesch
Journal:  Nutr Rev       Date:  2022-05-09       Impact factor: 6.846

7.  Dietary protein intake and health-related outcomes: a methodological protocol for the evidence evaluation and the outline of an evidence to decision framework underlying the evidence-based guideline of the German Nutrition Society.

Authors:  Anja Kroke; Annemarie Schmidt; Anna M Amini; Nicole Kalotai; Andreas Lehmann; Julia Haardt; Jürgen M Bauer; Heike A Bischoff-Ferrari; Heiner Boeing; Sarah Egert; Sabine Ellinger; Tilman Kühn; Sandrine Louis; Stefan Lorkowski; Katharina Nimptsch; Thomas Remer; Matthias B Schulze; Roswitha Siener; Gabriele I Stangl; Dorothee Volkert; Armin Zittermann; Anette E Buyken; Bernhard Watzl; Lukas Schwingshackl
Journal:  Eur J Nutr       Date:  2022-01-14       Impact factor: 5.614

8.  Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies.

Authors:  Jennifer J Lee; Tauseef A Khan; Nema McGlynn; Vasanti S Malik; James O Hill; Lawrence A Leiter; Per Bendix Jeppesen; Dario Rahelić; Hana Kahleová; Jordi Salas-Salvadó; Cyril W C Kendall; John L Sievenpiper
Journal:  Diabetes Care       Date:  2022-08-01       Impact factor: 17.152

9.  The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: A systematic review.

Authors:  Kim Donoghue; Laura Hermann; Eileen Brobbin; Colin Drummond
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

Review 10.  Role of Dietary Carotenoids in Frailty Syndrome: A Systematic Review.

Authors:  Roberta Zupo; Fabio Castellana; Sara De Nucci; Annamaria Sila; Simona Aresta; Carola Buscemi; Cristiana Randazzo; Silvio Buscemi; Vincenzo Triggiani; Giovanni De Pergola; Claudia Cava; Madia Lozupone; Francesco Panza; Rodolfo Sardone
Journal:  Biomedicines       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.